(Q42995854)

12 November 2017

HCV liver infection and liver steatosis: evidence for indirect mechanisms in genotype 3? (English)

1 reference

12 November 2017

1 reference

Grassi A

1

1 reference

12 November 2017

Ballardini G

2

1 reference

12 November 2017

Susca M

3

1 reference

12 November 2017

Bianchini F

4

1 reference

12 November 2017

Bianchi FB

6

1 reference

12 November 2017

Lenzi M

7

1 reference

12 November 2017

Bonoli S

5

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

Alimentary Pharmacology & Therapeutics

12 November 2017

1 reference

12 November 2017

22 Suppl 2

1 reference

12 November 2017

79-82

1 reference

Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

12 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02603.X

Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02603.X

Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02603.X

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02603.X

Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02603.X

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02603.X

Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02603.X

Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02603.X

Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02603.X

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02603.X

Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02603.X

Hepatocellular codistribution of c100, c33, c22, and NS5 hepatitis C virus antigens detected by using immunopurified polyclonal spontaneous human antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02603.X

Hepatitis C virus core protein induces hepatic steatosis in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02603.X

10.1111/J.1365-2036.2005.02603.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference